Immunology Investor Event

Building an industry-leading immunology pipeline Injectable Topical DupixentⓇ Anti-IL4/IL13 mAb Oral Priority asset ΣΟ KevzaraⓇ Anti-IL6 mAb Aubagio® LemtradaⓇ EnjaymoⓇ Anti-complement C1s mAb DupixentⓇ Anti-IL4/IL13 mAb rilzabrutinib BTK inhibitor itepekimab Anti-IL33 mAb tolebrutinib BTK inhibitor MARKETED As of March 29, 2022 58 Immunology Investor Event REGISTRATION & PHASE III 8 amlitelimab Anti-OX40L mAb rilzabrutinib BTK inhibitor SAR'727 BTK inhibitor SAR'088 Complement C1s inhibitor SAR'344 Anti-CD40L mAb eclitasertib RIPK1 inhibitor SAR'820 u RIPK1 inhibitor 03 SAR'726 Anti-IL13/OX40L NanobodyⓇ VHH SAR'765 Anti-IL13/TSLP Nanobody® VHH SAR'970 Anti-TNF/OX40L NanobodyⓇ VHH Anti-TNF/IL23 NanobodyⓇ VHH SAR'999 SAR'336 Non-beta IL2 SAR'656 IRAK4 degrader SAR'566 TNF inhibitor PHASE I & II sanofi

View entire presentation